Literature DB >> 12427470

Entamoeba histolytica: sequence conservation of the Gal/GalNAc lectin from clinical isolates.

David L Beck1, Mehmet Tanyuksel, Aaron J Mackey, Rashidul Haque, Nino Trapaidze, William R Pearson, Brendan Loftus, William A Petri.   

Abstract

The Gal/GalNAc lectin gene of Entamoeba histolytica is a major amebic virulence protein responsible for interaction with host tissues. We investigated sequence differences in the Gal/GalNAc lectin heavy subunit in three isolates from Bangladesh and one isolate from Georgia, each of which was determined to be genetically distinct by SREHP AluI digestion. Interestingly, we observed only slight genetic diversity in the lectin gene as compared with the HM1:IMSS laboratory strain, originally a clinical isolate from Mexico. Genetic conservation of the Gal/GalNAc lectin between isolates may reflect that the lectin is under strong functional selection or possibly, that E. histolytica is a clonal population. Sequence conservation of the lectin indicates that immune responses against it should be cross-protective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427470     DOI: 10.1016/s0014-4894(02)00113-3

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  10 in total

1.  Coding and noncoding genomic regions of Entamoeba histolytica have significantly different rates of sequence polymorphisms: implications for epidemiological studies.

Authors:  Dhruva Bhattacharya; Rashidul Haque; Upinder Singh
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 2.  The future for vaccine development against Entamoeba histolytica.

Authors:  Jeanie Quach; Joëlle St-Pierre; Kris Chadee
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

3.  Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine.

Authors:  L Barroso; M Abhyankar; Z Noor; K Read; K Pedersen; R White; C Fox; W A Petri; D Lyerly
Journal:  Vaccine       Date:  2013-07-01       Impact factor: 3.641

4.  Entamoeba histolytica infection in children and protection from subsequent amebiasis.

Authors:  Rashidul Haque; Dinesh Mondal; Priya Duggal; Mamun Kabir; Shantanu Roy; Barry M Farr; R Bradley Sack; William A Petri
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Comparative genomic hybridizations of Entamoeba strains reveal unique genetic fingerprints that correlate with virulence.

Authors:  Preetam H Shah; Ryan C MacFarlane; Dhruva Bhattacharya; John C Matese; Janos Demeter; Suzanne E Stroup; Upinder Singh
Journal:  Eukaryot Cell       Date:  2005-03

6.  Evaluation of recombinant fragments of Entamoeba histolytica Gal/GalNAc lectin intermediate subunit for serodiagnosis of amebiasis.

Authors:  Hiroshi Tachibana; Xun-Jia Cheng; Gohta Masuda; Noriyuki Horiki; Tsutomu Takeuchi
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

7.  Molecular epidemiology of amebiasis.

Authors:  Ibne Karim M Ali; C Graham Clark; William A Petri
Journal:  Infect Genet Evol       Date:  2008-05-14       Impact factor: 3.342

8.  Genomic diversity of the human intestinal parasite Entamoeba histolytica.

Authors:  Gareth D Weedall; C Graham Clark; Pia Koldkjaer; Suzanne Kay; Iris Bruchhaus; Egbert Tannich; Steve Paterson; Neil Hall
Journal:  Genome Biol       Date:  2012-05-25       Impact factor: 13.583

9.  Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Mark T Orr; Susan Lin; Mohammed O Suraju; Adrian Simpson; Molly Blust; Tiep Pham; Jeffrey A Guderian; Mark A Tomai; James Elvecrog; Karl Pedersen; William A Petri; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-06-05       Impact factor: 7.344

10.  Genetic Diversity and Gene Family Expansions in Members of the Genus Entamoeba.

Authors:  Ian W Wilson; Gareth D Weedall; Hernan Lorenzi; Timothy Howcroft; Chung-Chau Hon; Marc Deloger; Nancy Guillén; Steve Paterson; C Graham Clark; Neil Hall
Journal:  Genome Biol Evol       Date:  2019-03-01       Impact factor: 3.416

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.